Publications

Comparative Study
Journal Article
Ppublish 44 citations
Electronic publication date
July 1, 1992

View on Pubmed.gov 1510428 | View on doi.org 10.1128/AAC.36....

In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum.

Search for publications in this journal Antimicrob Agents Chemother - 36(7):1358-66

  • T Iwahi

    Search for this expert
    1
  • K Okonogi

    Search for this expert
  • T Yamazaki
  • S Shiki

    Search for this expert
  • M Kondo
  • A Miyake

    Search for this expert
  • A Imada

    Search for this expert

Abstract

SCE-2787, a new cephalosporin having a condensed azolium moiety in the 3 position and an aminothiadiazolyl group in the 7 beta side chain, was evaluated for its in vitro and in vivo activities in comparison with those of ceftazidime, flomoxef, cefpirome, and E1040. Against methicillin-susceptible strains of Staphylococcus aureus and Staphylococcus epidermidis, SCE-2787 was more active than ceftazidime and E1040 and was as active as flomoxef and cefpirome, with MICs for 90% of strains tested (MIC90s) being 1.56 micrograms/ml or less. SCE-2787 was also active against Pseudomonas aeruginosa, for which the MIC90 was 6.25 micrograms/ml, which was lower than that of cefpirome and comparable to that of ceftazidime. SCE-2787 was marginally active against methicillin-resistant strains of staphylococci and Enterococcus faecalis, although its MIC90s were the lowest among those of the antibiotics tested. The activities of SCE-2787 against Streptococcus species, most members of the family Enterobacteriaceae, and Haemophilus influenzae exceeded those of ceftazidime and flomoxef and were comparable to those of cefpirome. Furthermore, MIC90s of SCE-2787 were significantly lower than those of ceftazidime for ceftazidime-resistant isolates of Citrobacter freundii and Enterobacter cloacae. SCE-2787 was resistant to hydrolysis by various types of beta-lactamases, including the Bush group 1 beta-lactamases, and had low affinities for these enzymes, with Km or Ki values of greater than 100 microM. The in vitro activity of SCE-2787 was reflected in its efficacy in mouse protection tests. Thus, SCE-2787 appears to be a promising cephalosporin that should be further evaluated in clinical trials.

References

Antimicrob Agents Chemother. 1986 Nov;30(5):713-8

Eur J Clin Microbiol. 1987 Aug;6(4):439-45

J Antimicrob Chemother. 1985 Mar;15(3):305-10

Antimicrob Agents Chemother. 1985 May;27(5):821-7

Cited by 44 citations (total)

Journal Article Review

A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Electronic publication date June 1, 1995

Search for publications in this journal Antimicrob Agents Chemother

K Bush [...] A A Medeiros et al.

Comparative Study Journal Article

Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals.

Electronic publication date November 1, 1992

Search for publications in this journal Antimicrob Agents Chemother

Y Kita [...] A Imada et al.

The pharmacokinetic properties of SCE-2787 administered intravenously at a dose of 20 mg/kg of body weight were studied with mice,...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Substances